Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2021

View Archived Issues

GeneTACs show promise for treating myotonic dystrophy type 1

Jiangsu Simcere Pharmaceutical R&D patents DNA repair protein RAD51 homolog 1 inhibitors

Sphingomyelin-derived camptothecin nanovesicle platform for improved cancer immunochemotherapy

Unveiling immune-malignant cell hubs underlying cancer immunologic and tumorigenic processes

Engineered macrophages for chemo/photo/immunotherapy of primary and bone metastatic breast cancer

JMJD1C demethylase as novel target for AR-negative prostate cancer

Inflazome patents NLRP3 inflammasome inhibitors

Janssen Pharmaceutica presents Mcl-1 inhibitors

Shanghai Henlius Biotech discloses CD137-targeting antibodies

MASP2 levels are increased in children with severe asthma

Metabolomics study reveals dementia-linked metabolites

PRS-220 shows favorable PK and biodistribution in fibrotic lung models

KIM-1 unveiled as a marker of COVID-19 severity

Combined inhibition of RIPK1 and ferroptosis as potential therapeutic strategy for AKI

ARN-19702 shows broad analgesic effect in animal models of pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026
SERCA inhibitor shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, researchers...